Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies
about
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Does design matter? Systematic evaluation of the impact of analytical choices on effect estimates in observational studiesNonalcoholic fatty liver disease: a comprehensive review of a growing epidemicThe risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studiesShould antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without?PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertaintySafety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitusβ-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat dietPeroxisome proliferator-activated receptor-gamma agonists suppress tissue factor overexpression in rat balloon injury model with paclitaxel infusionRisk of Bias in Systematic Reviews of Non-Randomized Studies of Adverse Cardiovascular Effects of Thiazolidinediones and Cyclooxygenase-2 Inhibitors: Application of a New Cochrane Risk of Bias ToolIdentifying plausible adverse drug reactions using knowledge extracted from the literatureRational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms.Identification of major cardiovascular events in patients with diabetes using primary care data.Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis.Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity.Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.Diabetes and cardiovascular risk: are dipeptidyl peptidase-4 inhibitors beneficial?Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trialA systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone.Antipsychotics inhibit glucose transport: Determination of olanzapine binding site in Staphylococcus epidermidis glucose/H(+) symporter.Importance of Beta Cell Function for the Treatment of Type 2 DiabetesProduction of 7-O-methyl aromadendrin, a medicinally valuable flavonoid, in Escherichia coli.Formation and signaling actions of electrophilic lipidsCardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studiesThe insulin receptor: a new target for cancer therapy.Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six CountriesRelief of diabetes by duodenal-jejunal bypass sleeve implantation in the high-fat diet and streptozotocin-induced diabetic rat model is associated with an increase in GLP-1 levels and the number of GLP-1-positive cells.Short-Term Therapy with Rosiglitazone, a PPAR-γ Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar RatsCritical evaluation of the role of acarbose in the treatment of diabetes: patient considerations.Drug-induced mitochondrial dysfunction and cardiotoxicity.Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.Insulin resistance: metabolic mechanisms and consequences in the heart.Interpreting adverse signals in diabetes drug development programs.Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials.Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR- γ Agonist against MPTP.Net improvement of correct answers to therapy questions after pubmed searches: pre/post comparison.Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitusField-wide meta-analyses of observational associations can map selective availability of risk factors and the impact of model specifications.
P2860
Q22241288-8234A7BD-E47A-4FFF-8F7C-7D71E7178849Q24288975-68639A02-C0B0-431C-965C-D4840060C53EQ24563381-6C16B3F1-7C2D-494E-BE6A-1606704A0E74Q26999933-E67F6693-65B0-4401-A8EF-0E25F9A00991Q27022813-A1AF2089-D74B-4480-8F8C-53835E45A09AQ27024799-7F4308F7-C4EC-4D88-BA8A-BC2C05424646Q27027877-B271E231-7847-4C00-BF73-115188138DA6Q27692665-FDE16707-8BCC-46D8-B188-D2D89DD44423Q28477781-A5A92799-7E76-4918-A71B-10BC722C2B8FQ28478187-C3819205-278E-4D99-B82B-3898DB1BBF97Q28551188-657ADDAA-4036-469C-86F8-A0D5E977A4E6Q28650098-12DF72FE-9C0B-4EE8-B316-80D5BF3A4B0EQ30410721-BF7046CA-01BB-42A7-8D0F-1EB026F4196DQ31067093-A0E5690E-035C-4386-B6E4-9AD851D46C27Q33687578-29D09337-4877-403A-A24B-82DC006BADAEQ33961458-17126B2A-D1F6-46EA-8FE1-AF0E5DBE3B58Q34099031-731BC01D-490C-4BCD-AC9A-89FFFBE4D3BAQ34612834-DEEA7265-EA2F-4435-A302-21222C128EF8Q34803585-9823A085-8AE9-40C4-981F-9921BAAF934FQ35189862-AD584B10-D0A0-4D81-9718-791F999906ACQ35547830-51B5CB8C-B27C-4448-AB9C-8ABACD054352Q35667116-7BE6DD60-7F8C-4B5D-B05A-3D8124898E9FQ35688880-61BB3088-5C7D-4F11-816E-373BA503E32BQ35804051-D80ADDCA-0150-4DB6-B486-14284674024AQ35894680-6040FAE0-229D-49CE-A533-D0E1DA4800B4Q35972002-B3F903F2-DC01-4232-91BC-701F3A22F935Q36034337-48BAF376-6D51-40FA-A249-ABFACEA3339FQ36081345-EC264A8C-344C-4980-9911-45A025958F14Q36203979-A5853708-5DEC-4518-89D3-C839D9F5F878Q36333089-E3C8A627-0ECE-4A1D-9CC0-B44CC14ED82EQ36339445-F13018DD-0729-4115-A889-9A375B854BF0Q36383322-5B4A4C44-6EA6-4072-A59F-4DE6FBCCD2B6Q36639308-8B527438-8DAD-4B36-A173-A6697B5A715FQ36821424-AF17CA9E-8833-4E4E-A8FD-8EA2462E866DQ36942266-F2A0B018-A339-4DD9-80F5-66907CCE9C21Q37023878-A6088D35-0759-4A74-84F5-F23A914B47ABQ37256315-8B4A57A0-D781-4490-B318-50CCA5203C68Q37344908-CB09CE9F-C11B-4ED0-8992-C62966868F85Q37371587-CD709AC0-4DC0-406F-B871-B1CC46ADF6C6Q37412229-4B4F1DA5-9C3E-47A1-9E3E-1FEFAA4A9C7B
P2860
Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Comparative cardiovascular eff ...... lysis of observational studies
@ast
Comparative cardiovascular eff ...... lysis of observational studies
@en
Comparative cardiovascular eff ...... lysis of observational studies
@nl
type
label
Comparative cardiovascular eff ...... lysis of observational studies
@ast
Comparative cardiovascular eff ...... lysis of observational studies
@en
Comparative cardiovascular eff ...... lysis of observational studies
@nl
prefLabel
Comparative cardiovascular eff ...... lysis of observational studies
@ast
Comparative cardiovascular eff ...... lysis of observational studies
@en
Comparative cardiovascular eff ...... lysis of observational studies
@nl
P2860
P31
P921
P3181
P356
P1433
P1476
Comparative cardiovascular eff ...... lysis of observational studies
@en
P2093
Yoon Kong Loke
P2860
P3181
P356
10.1136/BMJ.D1309
P407
P433
P5008
P577
2011-03-17T00:00:00Z